Searching News Database: Opioid Dependence
HSMN NewsFeed - 30 Aug 2023
Alkermes Announces Settlement With Teva Related to VIVITROL(R) Patent Litigation
Alkermes Announces Settlement With Teva Related to VIVITROL(R) Patent Litigation
HSMN NewsFeed - 22 Feb 2019
Mylan Launches Generic Suboxone(R) Sublingual Film to Treat Opioid Dependence
Mylan Launches Generic Suboxone(R) Sublingual Film to Treat Opioid Dependence
HSMN NewsFeed - 2 Oct 2018
Titan Strengthens Executive Leadership Team with Appointment of Chief Commercial Officer
Titan Strengthens Executive Leadership Team with Appointment of Chief Commercial Officer
HSMN NewsFeed - 1 Oct 2018
Orexo Internalizes Contract Field Force in the US to Further Strengthen the Commercial Organization
Orexo Internalizes Contract Field Force in the US to Further Strengthen the Commercial Organization
HSMN NewsFeed - 21 Sep 2018
CHMP Recommends Approval of Buvidal(R) (CAM2038) for the Treatment of Opioid Dependence
CHMP Recommends Approval of Buvidal(R) (CAM2038) for the Treatment of Opioid Dependence
HSMN NewsFeed - 6 Aug 2018
US WorldMeds and Salix Announce U.S. Launch of LUCEMYRA(TM) (lofexidine) 0.18 Mg Tablets
US WorldMeds and Salix Announce U.S. Launch of LUCEMYRA(TM) (lofexidine) 0.18 Mg Tablets
HSMN NewsFeed - 14 May 2018
Accomplished Global Pharmaceutical Executive, Federico Seghi Recli, Appointed To Titan's Board
Accomplished Global Pharmaceutical Executive, Federico Seghi Recli, Appointed To Titan's Board
HSMN NewsFeed - 22 Jan 2018
Titan In Discussions With Braeburn Regarding U.S. Probuphine(R) Commercialization
Titan In Discussions With Braeburn Regarding U.S. Probuphine(R) Commercialization
HSMN NewsFeed - 11 Oct 2017
First Patient Treated With Titan Pharmaceuticals' Subdermal Implant For Parkinson's Disease
First Patient Treated With Titan Pharmaceuticals' Subdermal Implant For Parkinson's Disease
HSMN NewsFeed - 6 Oct 2016
U.S. FDA Approves Orexo's Low Dose ZUBSOLV(R) Buprenorphine and Naloxone Sublingual Tablets (CIII)
U.S. FDA Approves Orexo's Low Dose ZUBSOLV(R) Buprenorphine and Naloxone Sublingual Tablets (CIII)
HSMN NewsFeed - 20 Sep 2016
Lannett Announces Approval For Buprenorphine And Naloxone Sublingual Tablets, 2 mg/0.5 mg And 8 mg/2 mg
Lannett Announces Approval For Buprenorphine And Naloxone Sublingual Tablets, 2 mg/0.5 mg And 8 mg/2 mg
HSMN NewsFeed - 17 Mar 2016
Elite Announces U.S. FDA Priority Review Designation for SequestOx(TM) NDA
Elite Announces U.S. FDA Priority Review Designation for SequestOx(TM) NDA
HSMN NewsFeed - 19 Jan 2016
Akorn Launches Buprenorphine/Naloxone Sublingual Tablets and Tobramycin Injection
Akorn Launches Buprenorphine/Naloxone Sublingual Tablets and Tobramycin Injection
HSMN NewsFeed - 3 Dec 2013
BioDelivery Sciences Announces Hiring of David Acheson as Vice President of Sales and Managed Markets
BioDelivery Sciences Announces Hiring of David Acheson as Vice President of Sales and Managed Markets
HSMN NewsFeed - 20 Aug 2013
Mallinckrodt Pharmaceuticals Signs Distribution Agreement with Amneal Pharmaceuticals LLC
Mallinckrodt Pharmaceuticals Signs Distribution Agreement with Amneal Pharmaceuticals LLC
HSMN NewsFeed - 5 Jul 2013
U.S. FDA Approves Zubsolv(R) for the Maintenance Treatment of Opioid Dependence
U.S. FDA Approves Zubsolv(R) for the Maintenance Treatment of Opioid Dependence
HSMN NewsFeed - 15 Oct 2012
BioDelivery Sciences Announces the Launch of BREAKYL (BEMA Fentanyl) in the E.U.
BioDelivery Sciences Announces the Launch of BREAKYL (BEMA Fentanyl) in the E.U.
HSMN NewsFeed - 17 Jun 2011
Titan Pharmaceuticals Provides Update on Confirmatory Phase 3 Study of Probuphine
Titan Pharmaceuticals Provides Update on Confirmatory Phase 3 Study of Probuphine
HSMN NewsFeed - 4 Aug 2008
Alkermes Announces Approval of VIVITROL(R) for the Treatment of Alcohol Dependence in Russia
Alkermes Announces Approval of VIVITROL(R) for the Treatment of Alcohol Dependence in Russia
HSMN NewsFeed - 7 Jan 2008
Alkermes Announces Agreement for the Commercialization of VIVITROL in Russia/CIS
Alkermes Announces Agreement for the Commercialization of VIVITROL in Russia/CIS
HSMN NewsFeed - 12 Jan 2007
Catalyst Pharmaceutical Partners, Inc. Adds Thomas Kosten, M.D. to Its Scientific Advisory Board
Catalyst Pharmaceutical Partners, Inc. Adds Thomas Kosten, M.D. to Its Scientific Advisory Board
HSMN NewsFeed - 6 Oct 2006
SUBOXONE(R) (Buprenorphine/Naloxone) Approved In European Union for Treatment of Opioid Dependence
SUBOXONE(R) (Buprenorphine/Naloxone) Approved In European Union for Treatment of Opioid Dependence
Additional items found! 8
Members Archive contains
8 additional stories matching:
Opioid Dependence
(Password required)
Opioid Dependence
(Password required)